Partner Headlines - ARNA

  1. Orexigen Soars On Obesity Drug's Surprise Health Boon

    IBD
  2. Morning Market Losers

    Benzinga
  3. Benzinga's Top #PreMarket Losers

    Benzinga
  4. 10 Stocks You Should Be Watching Today

    Benzinga
  5. Arena Pharmaceuticals Misses Q4 Expectations

    Benzinga
  6. Earnings Scheduled For March 2, 2015

    Benzinga
  7. CNBC's Stock Pops & Drops From January 21

    Benzinga
  8. Mid-Afternoon Market Update: Alnylam Pharmaceuticals Drops Following ...

    Benzinga
  9. 4 More Biotech Secondaries Traders Are Watching

    Benzinga
  10. Mid-Day Market Update: U.S. Stocks Surge; Netflix Shares Jump ...

    Benzinga
  11. Mid-Morning Market Update: Markets Mixed; UnitedHealth Profit ...

    Benzinga
  12. Morning Market Losers

    Benzinga
  13. Wednesday Morning Movers: Netflix Flying High

    Benzinga
  14. Arena Pharmaceuticals Announces Agreement to Sell Common Stock

    Benzinga
  15. Benzinga's Top #PreMarket Losers

    Benzinga
  16. Tuesday's After-Hours Movers: Netflix Leads The Pack

    Benzinga
  17. 5 Obesity Stocks Investors Are Watching

    Benzinga
  18. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  19. Mid-Afternoon Market Update: Dow Jumps Over 200 Points After ...

    Benzinga
  20. Mid-Day Market Update: J C Penney Jumps On Strong Holiday Sales; ...

    Benzinga
  21. Mid-Morning Market Update: Markets Surge; Monsanto Profit Tops ...

    Benzinga
  22. Morning Market Gainers

    Benzinga
  23. Benzinga's Top #PreMarket Gainers

    Benzinga
  24. 4 Potential Blockbuster Drugs The FDA Just Approved

    IBD
  25. Orexigen Therapeutics Gains On Diet Pill Nod From European Committee

    Benzinga
  26. Pharmaceutical Stocks In Play Following Merck/Cubist Deal

    Benzinga
  27. What's Driving Orexigen Therapeutics Higher?

    Benzinga
  28. Benzinga's Top #PreMarket Gainers

    Benzinga
  29. Arena Pharma Reports Q3 EPS Loss $0.05, Revenues Of $8.16M Vs. ...

    Benzinga
  30. Earnings Scheduled For November 3, 2014

    Benzinga
  31. 3 Pharma Companies Fighting Obesity

    Benzinga
  32. Benzinga's Top #PreMarket Gainers

    Benzinga
  33. Bank Of America Q3 Small & Mid-Cap Biotech Preview

    Benzinga
  34. Eisai And Arena Pharmaceuticals Announce Publication Of Pooled ...

    Benzinga
  35. Earnings Scheduled For August 1, 2014

    Benzinga
  36. Benzinga's Top #PreMarket Losers

    Benzinga
  37. Markets Marginally Lower Ahead Of Earnings Season

    Benzinga
  38. Arena Pharmaceutical Shares Dive On News CEO Sold 40% Of His ...

    Benzinga
  39. Benzinga's Top #PreMarket Losers

    Benzinga
  40. Events Scheduled for Week of Jun. 16th to Jun. 20th

    Benzinga
  41. FDA delays Orexigen drug

    IBD
  42. Is Arena Pharmaceuticals A Biotech Stock To Watch?

    Benzinga
  43. Orexigen Obesity Drug Decision Delayed By FDA

    IBD
  44. Orexigen Shares Plummet Following FDA Decision; Competition Gets ...

    Benzinga
  45. Arena Pharma Posts Q1 Loss Of $0.12/Share, Misses By ~$0.02/Share

    Benzinga
  46. Earnings Scheduled For May 12, 2014

    Benzinga
  47. Mornings Movers for Feb. 28, 2014: CETV, OTVI, MELI, REGI, GALE ...

    Benzinga
  48. Benzinga's Top #PreMarket Losers

    Benzinga
  49. Earnings Scheduled For February 27, 2014

    Benzinga
  50. Bad Earnings Weigh In On Diet Stocks

    Benzinga
  51. Top Trending Tickers On StockTwits For February 14

    Benzinga
  52. #PreMarket Primer: Friday, February 14: A Turnaround

    Benzinga
  53. Arena Pharmaceuticals Announces Filing for Marketing Authorization ...

    Benzinga
  54. Celgene To Release Earnings At J.P. Morgan Event Mon.

    IBD
  55. The Top Five Drug Launches Of 2013

    IBD
  56. (ARNA) Initiated with a Buy, (ICLD, FONR) Strong Performance ...

    GuruFocus
  57. Benzinga's Top #PreMarket Gainers

    Benzinga
  58. Market Wrap For November 11: Relative Quiet as Traders and Investors ...

    Benzinga
  59. Market Wrap For November 8: Markets Erase Thursday's Losses; ...

    Benzinga
  60. Arena Pharmaceuticals, Eisai Expand Marketing and Supply Agreement ...

    Benzinga
  61. Nasdaq Leads Stocks Lower; Twitter IPO Opens To 80% Gain

    IBD
  62. How Arena’s “$3 Billion” Belviq Withered

    YCharts
  63. Benzinga's Top #PreMarket Losers

    Benzinga
  64. Market Wrap For Tuesday, October 15: Earnings Reports And White ...

    Benzinga
  65. Mid-Afternoon Market Update: Tumi Holdings Rises Amid Market ...

    Benzinga
  66. Mid-Morning Market Update: Markets Slip; Citigroup Profit Misses ...

    Benzinga
  67. UPDATE: Arena Says Eisai Will Double BELVIQ Sales Force to 4 ...

    Benzinga
  68. Vivus Weighs In As a Leader for Diet Pills, Cowen Upgrades and ...

    Benzinga
  69. Obesity Drug Stocks Jump As Cowen Gets Bullish

    IBD
  70. Benzinga's Top Pre-Market Losers

    Benzinga
  71. Market Wrap For September 30: Debt Ceiling And Government Shutdown ...

    Benzinga
  72. Mid-Afternoon Market Update: Mellanox Rallies As Market Remains ...

    Benzinga
  73. Mid-Day Market Update: Dow Falls Over 100 Points; Active Network ...

    Benzinga
  74. Mid-Morning Market Update: Markets Open Lower; Cal-Maine Q1 Net ...

    Benzinga
  75. UPDATE: Credit Suisse Lowers PT on Arena Pharmaceuticals Following ...

    Benzinga
  76. Arena Pharma Offers Update on Eisai Launch of BELVIQ, Says Placing ...

    Benzinga
  77. Stocks Hitting 52-Week Lows

    Benzinga
  78. BMO Considers Recent Sales Data on Arena's Belviq, Maintains ...

    Benzinga
  79. CEO Shift Aside, Whose Weight-Loss Pill’s Ahead

    YCharts
  80. Stocks Hitting 52-Week Lows

    Benzinga
  81. Stocks Hitting 52-Week Lows

    Benzinga
  82. Arena Pharma Reports Closing of Phase 1b Clinical Trial for APD811

    Benzinga
  83. Short Interest In Celgene, Onyx Continues To Shrink (CELG, ONXX, ...

    Benzinga
  84. It's Hard to Sell a Pill That Nobody's Heard Of

    YCharts
  85. Weekly Preview: Earnings Season Continues, Fed In Focus, Economic ...

    Benzinga
  86. Short Interest in Pharmacyclics Plunges (AMGN, ONXX, PCYC)

    Benzinga
  87. Short Interest Swings in Biotech Stocks (AMGN, CELG, ONXX)

    Benzinga
  88. Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)

    Benzinga
  89. Mid-Afternoon Market Update: Markets All Green, Research in Motion ...

    Benzinga
  90. Mid-Day Market Update: GenCorp Rises, Markets Erasing Losses

    Benzinga
  91. Mid-Morning Market Update: Verizon Misses Big on Earnings, Research ...

    Benzinga
  92. Vivus fell 4.2% to 13.72

    IBD
  93. Vivus Stock Drops On Downgrade; Rival Arena Rises

    IBD
  94. Measuring Social Network Buzz Over Pharma Stocks

    YCharts
  95. Vivus Stock Jumps On Latest Qsymia Shipment Numbers

    IBD
  96. Short Interest Swings in Biotech Stocks (CELG, GILD, REGN)

    Benzinga
  97. Benzinga's Top Pre-Market Gainers

    Benzinga
  98. The Best Small Cap Performers of 2012

    Benzinga
  99. Vivus Soars On Qsymia Anti-Obesity Drug Prescriptions

    IBD
  100. Acadia Pharma Rockets Higher on Study Results

    Benzinga
Trading Center